Clinical Report: Evaluating the Cost-Effectiveness of Universal Low-Dose CT Screening for Lung Cancer in Singapore
Overview
This study evaluates the cost-effectiveness of universal low-dose CT screening for lung cancer in Singapore, particularly focusing on never smokers. It employs a Markov cohort model to assess various screening strategies and their implications for lung cancer detection and treatment outcomes.
Background
Lung cancer is the leading cause of cancer mortality in Singapore, with 82% of cases diagnosed at late stages and a 5-year relative survival of 22.1% for males and 38.0% for females. Approximately 48% of cases occur in individuals who have never smoked, highlighting the need for effective screening strategies for this demographic.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
82% of lung cancer cases in Singapore are diagnosed at late stages.
Low-dose CT screening has shown a mortality reduction of 20% in landmark trials.
Only 38.1% of lung cancer patients in Singapore meet the NLST criteria for screening.
The TALENT trial achieved a 2.6% detection rate in never smokers, with 96.5% at stage I.
No validated risk prediction model exists for Asian never smokers.
LDCT screening in Taiwan raised early-stage incidence without reducing late-stage incidence, indicating potential overdiagnosis.
Clinical Implications
The findings highlight the necessity for tailored screening strategies that include never smokers to improve early detection rates. Clinicians should consider the implications of current guidelines and the potential need for revised screening protocols in diverse populations.
Conclusion
The study underscores the importance of evaluating screening strategies that encompass never smokers to enhance lung cancer detection and improve survival rates in Singapore.
